150 related articles for article (PubMed ID: 32328844)
1. A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
Zhu M; Molina JR; Dy GK; Croghan GA; Qi Y; Glockner J; Hanson LJ; Roos MM; Tan AD; Adjei AA
Invest New Drugs; 2020 Dec; 38(6):1755-1762. PubMed ID: 32328844
[TBL] [Abstract][Full Text] [Related]
2. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
Wang F; Molina J; Satele D; Yin J; Lim VS; Adjei AA
Invest New Drugs; 2019 Aug; 37(4):658-665. PubMed ID: 30382439
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
Jones SF; Spigel DR; Yardley DA; Thompson DF; Burris HA
Clin Adv Hematol Oncol; 2011 Nov; 9(11):845-52. PubMed ID: 22252616
[TBL] [Abstract][Full Text] [Related]
5. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
Jaeger-Lansky A; Cejka D; Ying L; Preusser M; Hoeflmayer D; Fuereder T; Koehrer S; Wacheck V
Cancer Biol Ther; 2010 Jun; 9(11):919-27. PubMed ID: 20404549
[TBL] [Abstract][Full Text] [Related]
6. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
Gadgeel SM; Lew DL; Synold TW; LoRusso P; Chung V; Christensen SD; Smith DC; Kingsbury L; Hoering A; Kurzrock R
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1089-96. PubMed ID: 24057042
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies.
Spigel D; Jones S; Hainsworth J; Infante J; Greco FA; Thompson D; Doss H; Burris H
Cancer Invest; 2011 May; 29(4):308-12. PubMed ID: 21469980
[TBL] [Abstract][Full Text] [Related]
8. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.
Tolcher AW; Bendell JC; Papadopoulos KP; Burris HA; Patnaik A; Jones SF; Rasco D; Cox DS; Durante M; Bellew KM; Park J; Le NT; Infante JR
Ann Oncol; 2015 Jan; 26(1):58-64. PubMed ID: 25344362
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.
McRee AJ; Davies JM; Sanoff HG; Goldberg RM; Bernard S; Dees EC; Keller K; Ivanova A; O'Neil BH
Cancer Chemother Pharmacol; 2014 Jul; 74(1):117-23. PubMed ID: 24819684
[TBL] [Abstract][Full Text] [Related]
10. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW
Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
Wood A; George S; Adra N; Chintala S; Damayanti N; Pili R
Invest New Drugs; 2020 Aug; 38(4):1108-1116. PubMed ID: 31654285
[TBL] [Abstract][Full Text] [Related]
13. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
Hollebecque A; Houédé N; Cohen EE; Massard C; Italiano A; Westwood P; Bumgardner W; Miller J; Brail LH; Benhadji KA; Soria JC
Eur J Cancer; 2014 Mar; 50(5):876-84. PubMed ID: 24456794
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Gerstner ER; Eichler AF; Plotkin SR; Drappatz J; Doyle CL; Xu L; Duda DG; Wen PY; Jain RK; Batchelor TT
J Neurooncol; 2011 Jun; 103(2):325-32. PubMed ID: 20821342
[TBL] [Abstract][Full Text] [Related]
15. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
Gupta P; Mulkey F; Hasserjian RP; Sanford BL; Vij R; Hurd DD; Odenike OM; Bloomfield CD; Owzar K; Stone RM; Larson RA;
Invest New Drugs; 2013 Oct; 31(5):1311-20. PubMed ID: 23700288
[TBL] [Abstract][Full Text] [Related]
17. Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.
Pedersen KS; Grierson PM; Picus J; Lockhart AC; Roth BJ; Liu J; Morton A; Chan E; Huffman J; Liang C; Wang-Gillam A; Tan B
Invest New Drugs; 2021 Oct; 39(5):1298-1305. PubMed ID: 33738668
[TBL] [Abstract][Full Text] [Related]
18. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
[No Abstract] [Full Text] [Related]
19. Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.
Sheng X; Yan X; Chi Z; Cui C; Si L; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Ding L; Mao L; Guo J
EBioMedicine; 2020 May; 55():102755. PubMed ID: 32335374
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
Place AE; Pikman Y; Stevenson KE; Harris MH; Pauly M; Sulis ML; Hijiya N; Gore L; Cooper TM; Loh ML; Roti G; Neuberg DS; Hunt SK; Orloff-Parry S; Stegmaier K; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Jul; 65(7):e27062. PubMed ID: 29603593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
